Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

  • Technology appraisal guidance
  • TA317
  • Published: 
Download guidance (PDF)

1 Guidance

This guidance replaces NICE technology appraisal guidance 182 issued in October 2009.

The review of prasugrel for treatment of acute coronary syndromes has resulted in a change in the guidance. See About this guidance for more information.

1.1 Prasugrel 10 mg in combination with aspirin is recommended as an option within its marketing authorisation, that is, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina [UA], non-ST segment elevation myocardial infarction [NSTEMI] or ST segment elevation myocardial infarction [STEMI]) having primary or delayed percutaneous coronary intervention.